Intervacc AB (publ) (IVACC.ST)
SEK 0.92
(-2.24%)
SEK 0.92
(-2.24%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -13.79 Million SEK | -2911.7% |
| 2022 | 3.36 Million SEK | -46.09% |
| 2021 | 6.24 Million SEK | 34.53% |
| 2020 | 4.64 Million SEK | 61.27% |
| 2019 | 2.87 Million SEK | -61.64% |
| 2018 | 7.5 Million SEK | -50.85% |
| 2017 | 15.27 Million SEK | -9.95% |
| 2016 | 16.96 Million SEK | -40.6% |
| 2015 | 28.55 Million SEK | -21.02% |
| 2014 | 36.15 Million SEK | 4450.64% |
| 2013 | 794.4 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -18.78 Million SEK | 103.26% |
| 2024 Q1 | -17.81 Million SEK | 17.88% |
| 2023 Q1 | 792 Thousand SEK | 140.08% |
| 2023 Q3 | -15.76 Million SEK | -2070.88% |
| 2023 Q4 | -21.69 Million SEK | -37.62% |
| 2023 FY | -94.67 Million SEK | -2911.7% |
| 2023 Q2 | 800 Thousand SEK | 1.01% |
| 2022 FY | 3.36 Million SEK | -46.09% |
| 2022 Q2 | 1.96 Million SEK | 22.7% |
| 2022 Q1 | 1.59 Million SEK | 16.97% |
| 2022 Q4 | -1.97 Million SEK | -210.89% |
| 2022 Q3 | 1.78 Million SEK | -9.17% |
| 2021 Q2 | 2.25 Million SEK | 58.76% |
| 2021 Q4 | 1.36 Million SEK | 13.73% |
| 2021 FY | 6.24 Million SEK | 34.53% |
| 2021 Q1 | 1.42 Million SEK | 36.37% |
| 2021 Q3 | 1.2 Million SEK | -46.72% |
| 2020 Q3 | 996 Thousand SEK | -32.66% |
| 2020 FY | 4.64 Million SEK | 61.27% |
| 2020 Q2 | 1.47 Million SEK | 31.35% |
| 2020 Q4 | 1.04 Million SEK | 4.62% |
| 2020 Q1 | 1.12 Million SEK | 6.53% |
| 2019 Q4 | 1.05 Million SEK | 1.54% |
| 2019 Q2 | -838 Thousand SEK | -151.76% |
| 2019 Q1 | 1.61 Million SEK | 140.43% |
| 2019 FY | 2.87 Million SEK | -61.64% |
| 2019 Q3 | 1.04 Million SEK | 224.22% |
| 2018 Q2 | 3.8 Million SEK | 179.37% |
| 2018 FY | 7.5 Million SEK | -50.85% |
| 2018 Q4 | 673.36 Thousand SEK | -59.55% |
| 2018 Q3 | 1.66 Million SEK | -56.25% |
| 2018 Q1 | 1.36 Million SEK | 586.79% |
| 2017 Q4 | 198.33 Thousand SEK | -95.45% |
| 2017 Q2 | 6.82 Million SEK | 75.46% |
| 2017 FY | 15.27 Million SEK | -9.95% |
| 2017 Q1 | 3.89 Million SEK | 244.94% |
| 2017 Q3 | 4.35 Million SEK | -36.18% |
| 2016 Q2 | 7.04 Million SEK | 130.24% |
| 2016 Q4 | -2.68 Million SEK | -136.95% |
| 2016 FY | 16.96 Million SEK | -40.6% |
| 2016 Q3 | 7.26 Million SEK | 3.06% |
| 2016 Q1 | 3.06 Million SEK | 0.0% |
| 2015 FY | 28.55 Million SEK | -21.02% |
| 2014 FY | 36.15 Million SEK | 4450.64% |
| 2013 FY | 794.4 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Active Biotech AB (publ) | -1.67 Million SEK | -723.522% |
| Amniotics AB (publ) | -1.93 Million SEK | -614.715% |
| BioArctic AB (publ) | 346.31 Million SEK | 103.983% |
| Calliditas Therapeutics AB (publ) | 1.12 Billion SEK | 101.221% |
| Camurus AB (publ) | 1.58 Billion SEK | 100.873% |
| Cantargia AB (publ) | -3.45 Million SEK | -299.71% |
| Scandinavian ChemoTech AB (publ) | 1.65 Million SEK | 931.966% |
| CombiGene AB (publ) | -21.29 Million SEK | 35.211% |
| Diamyd Medical AB (publ) | -3.58 Million SEK | -285.307% |
| Genovis AB (publ.) | 54 Million SEK | 125.544% |
| Guard Therapeutics International AB (publ) | -15 Thousand SEK | -91860.0% |
| Mendus AB (publ) | 28.48 Million SEK | 148.422% |
| Isofol Medical AB (publ) | -34.41 Million SEK | 59.919% |
| Kancera AB (publ) | -1.96 Million SEK | -601.985% |
| Karolinska Development AB (publ) | 2.8 Million SEK | 591.414% |
| LIDDS AB (publ) | -12.92 Million SEK | -6.748% |
| Lipum AB (publ) | 53 Thousand SEK | 26126.415% |
| Lipigon Pharmaceuticals AB (publ) | -5.11 Million SEK | -169.572% |
| Magle Chemoswed Holding AB (publ) | 9.96 Million SEK | 238.452% |
| NextCell Pharma AB | -43.74 Million SEK | 68.47% |
| OncoZenge AB (publ) | 3000.00 SEK | 459900.0% |
| Saniona AB (publ) | 11.78 Million SEK | 217.087% |
| Simris Alg AB (publ) | 2 Million SEK | 787.294% |
| Vicore Pharma Holding AB (publ) | -3.42 Million SEK | -303.215% |
| Xbrane Biopharma AB (publ) | 35.38 Million SEK | 138.979% |
| Xintela AB (publ) | 78 Thousand SEK | 17784.615% |
| Xspray Pharma AB (publ) | -9.19 Million SEK | -50.033% |
| Ziccum AB (publ) | -23.28 Million SEK | 40.763% |
| Asarina Pharma AB (publ) | -423 Thousand SEK | -3160.993% |
| Elicera Therapeutics AB (publ) | 11.21 Million SEK | 222.96% |
| Modus Therapeutics Holding AB (publ) | - SEK | Infinity% |
| Alligator Bioscience AB (publ) | -160.68 Million SEK | 91.416% |
| Sprint Bioscience AB (publ) | 41.78 Million SEK | 133.01% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 2.17 Million SEK | 735.375% |
| Corline Biomedical AB | 28.38 Million SEK | 148.605% |
| IRLAB Therapeutics AB (publ) | -122.73 Million SEK | 88.761% |
| Bio-Works Technologies AB (publ) | 26.82 Million SEK | 151.43% |
| Aptahem AB (publ) | 2.63 Million SEK | 624.357% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | 18014.286% |
| Fluicell AB (publ) | 1.73 Million SEK | 893.671% |
| Biovica International AB (publ) | 6.87 Million SEK | 300.582% |
| Spago Nanomedical AB (publ) | -23.28 Million SEK | 40.755% |
| AcouSort AB (publ) | 8.38 Million SEK | 264.43% |
| Abliva AB (publ) | -35.66 Million SEK | 61.321% |
| Egetis Therapeutics AB (publ) | -146.9 Million SEK | 90.61% |
| 2cureX AB (publ) | -37.48 Million SEK | 63.203% |
| I-Tech AB | 27.56 Million SEK | 150.04% |
| Hansa Biopharma AB (publ) | 70.95 Million SEK | 119.442% |
| Cyxone AB (publ) | 2.61 Million SEK | 628.303% |
| ExpreS2ion Biotech Holding AB (publ) | 3.4 Million SEK | 505.348% |
| Biosergen AB | -456 Thousand SEK | -2925.0% |
| Nanologica AB (publ) | -76 Thousand SEK | -18050.0% |
| SynAct Pharma AB | -778 Thousand SEK | -1673.008% |
| Annexin Pharmaceuticals AB (publ) | -193 Thousand SEK | -7047.15% |
| BioInvent International AB (publ) | 71.46 Million SEK | 119.303% |
| Stayble Therapeutics AB (publ) | - SEK | Infinity% |
| Alzinova AB (publ) | 19.87 Million SEK | 169.407% |
| Oncopeptides AB (publ) | 36.29 Million SEK | 138.001% |
| Pila Pharma AB (publ) | 1.46 Million SEK | 1042.844% |
| Ascelia Pharma AB (publ) | -1.04 Million SEK | -1214.967% |
| Diagonal Bio AB (publ) | 3.13 Million SEK | 540.281% |